Seelos Therapeutics, Inc.
SEEL · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $376 | $579 | $653 | $406 |
| % Growth | -35.1% | -11.3% | 60.8% | – |
| Cost of Goods Sold | $755 | $15 | $15 | $14 |
| Gross Profit | -$379 | $564 | $638 | $392 |
| % Margin | -100.8% | 97.4% | 97.7% | 96.6% |
| R&D Expenses | $966 | $3,525 | $5,918 | $10,022 |
| G&A Expenses | $2,549 | $3,109 | $2,746 | $2,987 |
| SG&A Expenses | $2,549 | $3,094 | $2,731 | $2,987 |
| Sales & Mktg Exp. | $0 | -$15 | -$15 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,515 | $6,619 | $8,649 | $13,009 |
| Operating Income | -$3,139 | -$6,055 | -$8,011 | -$12,603 |
| % Margin | -834.8% | -1,045.8% | -1,226.8% | -3,104.2% |
| Other Income/Exp. Net | $4,849 | $3,391 | $2,558 | $23,101 |
| Pre-Tax Income | $1,710 | -$2,664 | -$5,453 | $10,498 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $1,710 | -$2,664 | -$5,453 | $10,498 |
| % Margin | 454.8% | -460.1% | -835.1% | 2,585.7% |
| EPS | 0.36 | -0.92 | -1.89 | 2.33 |
| % Growth | 139.1% | 51.3% | -181.1% | – |
| EPS Diluted | 0.12 | -0.72 | -1.47 | 2.13 |
| Weighted Avg Shares Out | 864 | 2,882 | 2,882 | 4,511 |
| Weighted Avg Shares Out Dil | 2,515 | 3,708 | 3,708 | 4,938 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $10 | $12 | $36 |
| Interest Expense | $23 | $23 | $19 | $42 |
| Depreciation & Amortization | $15 | $15 | $15 | $14 |
| EBITDA | $1,748 | -$2,626 | -$5,419 | $10,554 |
| % Margin | 464.9% | -453.5% | -829.9% | 2,599.5% |